Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1426-1432, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gonschior, A. K.
Right arrow Articles by Sewing, K. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonschior, A. K.
Right arrow Articles by Sewing, K. F.

Clinical Chemistry, Vol 42, 1426-1432, Copyright © 1996 by American Association for Clinical Chemistry

Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients

AK Gonschior, U Christians, M Winkler, A Linck, J Baumann and KF Sewing
Institut fur Allgemeine Pharmakologie, Hannover, Germany.

The metabolite patterns of tacrolimus in blood were evaluated in 41 kidney and liver graft recipients. Trough concentrations of tacrolimus and its metabolites were measured by HPLC-mass spectrometry and microparticle enzyme immunoassay in parallel. A statistically significant correlation between results of both assays was observed for kidney and liver transplant patients (r = 0.77, P <0.001 and r = 0.71, P <0.001, respectively). The main metabolites in blood were demethyl, demethylhydroxy, didemethyl, didemethylhydroxy, and hydroxy tacrolimus. These metabolites added up to 42% (range 0-145%) of the tacrolimus concentration in liver transplant patients and to 44.8% (range 16-152%) in kidney transplant patients. During episodes of impaired liver function, concentrations of tacrolimus and its metabolites were increased compared with normal liver function, indicating accumulation of metabolites, in particular second-generation metabolites such as didemethyl and didemethylhydroxy tacrolimus. Stepwise regression analysis including tacrolimus, its metabolites, and liver function parameters suggested a model including serum activities of gamma- glutamyltransferase, alkaline phosphatase, and alanine aminotransferase as predictors for increased concentrations of demethyl tacrolimus, didemethyl tacrolimus, and the parent drug.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
N. W. Brown, C. E. Gonde, J. E. Adams, and J. M. Tredger
Low Hematocrit and Serum Albumin Concentrations Underlie the Overestimation of Tacrolimus Concentrations by Microparticle Enzyme Immunoassay versus Liquid Chromatography-Tandem Mass Spectrometry
Clin. Chem., March 1, 2005; 51(3): 586 - 592.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. D. MacFarlane, D. G. Scheller, D. L. Ersfeld, L. M. Shaw, R. Venkatarmanan, L. Sarkozi, R. Mullins, and B. R. Fox
Analytical Validation of the PRO-Trac II ELISA for the Determination of Tacrolimus (FK506) in Whole Blood
Clin. Chem., September 1, 1999; 45(9): 1449 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. Steimer
Performance and Specificity of Monoclonal Immunoassays for Cyclosporine Monitoring: How Specific Is Specific?
Clin. Chem., March 1, 1999; 45(3): 371 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
V. W. Armstrong, E. Schuetz, Q. Zhang, S. Groothuisen, C. Scholz, M. Shipkova, H. Aboleneen, and M. Oellerich
Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography–tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II)
Clin. Chem., December 1, 1998; 44(12): 2516 - 2523.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.